Delayed complete remission in a patient with multiple myeloma

We report a strikingly positive, late response to bortezomib in conjunction with pegylated liposomal doxorubicin in a 79‐year old woman with multiple myeloma (MM). The patient obtained a partial remission after eight courses of therapy and a complete remission about 10 months after the end of therap...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of clinical investigation 2008-12, Vol.38 (12), p.966-968
Hauptverfasser:	Ria, R., Vacca, A., Mangialardi, G., Dammacco, F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angiogenesis Antineoplastic Combined Chemotherapy Protocols Biological and medical sciences Boronic Acids - administration & dosage Bortezomib Doxorubicin - administration & dosage Doxorubicin - analogs & derivatives Female General aspects Humans immune response Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Medical sciences multiple myeloma Multiple Myeloma - drug therapy pegylated liposomal doxorubicin Polyethylene Glycols - administration & dosage Pyrazines - administration & dosage Remission Induction Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We report a strikingly positive, late response to bortezomib in conjunction with pegylated liposomal doxorubicin in a 79‐year old woman with multiple myeloma (MM). The patient obtained a partial remission after eight courses of therapy and a complete remission about 10 months after the end of therapy. This delayed complete remission may be similar to the spontaneous regression reported for other malignancies such as melanoma or lymphoma. We postulate that the immune response and a persistent anti‐angiogenic effect of bortezomib could well explain the delayed complete remission in our patient.
ISSN:	0014-2972 1365-2362
DOI:	10.1111/j.1365-2362.2008.02049.x